Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Joe E. who wrote (5134)	8/13/1998 12:10:00 PM
From: John Metcalf	Read Replies (1) of 6136

Excuse me for jumping in, Joe. In general, physicians advise HIV positive women not to become pregnant, because HIV is almost always transmitted to the child. Unprotected sex is also not advised. Protease inhibitors would not routinely be withheld to women of childbearing age, because they are advised to be cautious in procreation and against becoming pregnant. For those women who are pregnant and HIV-positive, there are studies showing that AZT is of some value in preventing transmission to the child. In regard to the recent press for Thalidomide, Celgene has approval for use in leprosy. Like HIV, leprosy is a serious condition in which reproduction is not recommended. Canada was not withholding the benefits of nelfinivir from people who needed it. Agouron has had an expanded access program in Canada in which 1,200 adults were receiving the drug (paid by AGPH). There has also been an expanded access program for children. AGPH's news release on Canadian approval did not mention the number of children in the program.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next